CIK 0001739410 · <br>Emerging growth company
Rallybio Corp
Sign in to watch- Ticker
- RLYB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851083789
- Phone
- 203- 859-3820
- Business address
- 234 CHURCH STREET, SUITE 1020, NEW HAVEN, CT, 06510
- Former names
- Rallybio Holdings, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,608
- in 1 filing
Net −$9,608. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-28 | Nash Christine A Director | Option exercise | +3,562 | $2.38 | $8K | 3,562 |
| 2026-10-28 | Nash Christine A Director | Option exercise · Option (Right to Buy) | −3,562 | 0 | ||
| 2026-10-27 | Uden Stephen Chief Executive Officer | Option exercise | +33,244 | $6.08 | $202K | 148,864 |
| 2026-10-27 | Uden Stephen Chief Executive Officer | Option exercise · Option (Right to Buy) | −33,244 | 0 | ||
| 2026-10-27 | Lieber Jonathan I Chief Financial Officer | Sale | −599 | $16.04 | $10K | 15,551 |
| 2026-10-26 | Lieber Jonathan I Chief Financial Officer | Grant or award | +2,500 | 16,150 | ||
| 2026-10-26 | Chung Wendy Director | Option exercise | +2,062 | $15.28 | $32K | 5,624 |
| 2026-10-26 | Chung Wendy Director | Option exercise · Option (Right to Buy) | −2,062 | 0 | ||
| 2026-10-16 | Soteropoulos Paula Director | Option exercise | +3,562 | $2.38 | $8K | 6,544 |
| 2026-10-16 | Soteropoulos Paula Director | Option exercise · Option (Right to Buy) | −3,562 | 0 | ||
| 2026-10-16 | Boudreau Helen M Director | Option exercise | +2,062 | $15.28 | $32K | 8,604 |
| 2026-10-16 | Boudreau Helen M Director | Option exercise · Option (Right to Buy) | −2,062 | 0 | ||
| 2026-10-12 | Hopfner Robert Lorne Director | Option exercise | +9,196 | $7.60 | $70K | 9,196 |
| 2026-10-12 | Hopfner Robert Lorne Director | Option exercise | +3,562 | $2.38 | $8K | 12,758 |
| 2026-10-12 | Hopfner Robert Lorne Director | Option exercise | +2,062 | $15.28 | $32K | 14,820 |
| 2026-10-12 | Hopfner Robert Lorne Director | Option exercise · Option (Right to Buy) | −9,196 | $0.56 | $5K | 0 |
| 2026-10-12 | Hopfner Robert Lorne Director | Option exercise · Option (Right to Buy) | −3,562 | 0 | ||
| 2026-10-12 | Hopfner Robert Lorne Director | Option exercise · Option (Right to Buy) | −2,062 | 0 | ||
| 2026-10-09 | Lieber Jonathan I Chief Financial Officer | Option exercise | +3,910 | $6.08 | $24K | 13,650 |
| 2026-10-09 | Lieber Jonathan I Chief Financial Officer | Option exercise · Option (Right to Buy) | −3,910 | 0 |
Page 2 of 11 · 216 trades